Garcia, Mar <br/><br/>
Proliferation predicts failure-free survival in mantle cell lymphoma patients treated with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine.  [electronic resource] 

 -  Cancer  Mar 2009 
 - 1041-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0008-543X 
<br/><br/><label>Standard No.: </label>10.1002/cncr.24141  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Cyclophosphamide--administration & dosage<br/>Cytarabine--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Disease-Free Survival<br/>Doxorubicin--administration & dosage<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Ki-67 Antigen--metabolism<br/>Lymphoma, Mantle-Cell--drug therapy<br/>Male<br/>Methotrexate--administration & dosage<br/>Middle Aged<br/>Prognosis<br/>Rituximab<br/>Survival Analysis<br/>Vincristine--administration & dosage